Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients

NCT02910557 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT02910557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02910557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Postmarketing Prospective Cohort Study of Melanoma Patients Treated With IMLYGIC® in Clinical Practice to Characterize Risk of Herpetic Infection Among Patients, Close Contacts, Health Care Providers & Long-term Safety in Treated Patients
Lead sponsor
Amgen
Phase
Observational
Overall status
Completed
Start date
August 10, 2017
Completion date
January 30, 2026
Enrollment
187 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

herpetic infection, melanoma